SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/13/21 Eloxx Pharmaceuticals, Inc. 424B5 1:623K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 424B5 Prospectus - Primary Offering or Shelf Securities HTML 309K - New Facts or Events
tm2115863-1_424b5 - none - 7.2656273s |
| | |
Per Share
|
| |
Total
|
| ||||||
Offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discounts and commissions(1)
|
| | | $ | | | | | $ | | | ||
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | |
| | | | | S-ii | | | |
| | | | | S-1 | | | |
| | | | | S-3 | | | |
| | | | | S-4 | | | |
| | | | | S-6 | | | |
| | | | | S-8 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-12 | | | |
| | | | | S-19 | | | |
| | | | | S-20 | | | |
| | | | | S-21 | | | |
| | | | | S-22 | | |
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | |
|
Offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share at March 31, 2021
|
| | | $ | 0.07 | | | | | | | | |
|
Pro forma net tangible book value per share at March 31, 2021
|
| | | $ | 0.06 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share after giving effect to this
offering |
| | | | | | | | | $ | | | |
|
Dilution per share to new investors in this offering
|
| | | | | | | | | $ | | | |
Underwriter
|
| |
Number
of Shares |
|
B. Riley Securities, Inc.
|
| | | |
Total
|
| | | |
| | |
Total
|
| |||||||||||||||
|
Per Share
|
| |
Without
Option |
| |
With
Option |
| |||||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discount
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds, before expenses and fees, to us
|
| | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | 1 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 10 | | | |
| | | | 17 | | | |
| | | | 22 | | | |
| | | | 25 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 28 | | |
This ‘424B5’ Filing | Date | Other Filings | ||
---|---|---|---|---|
6/14/21 | SC 13G | |||
Filed on: | 5/13/21 | 4, 8-K | ||
5/12/21 | ||||
4/1/21 | 3, 4, 8-K, 8-K/A, DEF 14A, DEFA14A | |||
3/31/21 | 10-Q | |||
12/31/20 | 10-K | |||
8/12/20 | 8-K | |||
6/17/20 | 8-K | |||
3/25/20 | 8-K | |||
11/26/18 | EFFECT | |||
11/14/18 | ||||
9/30/18 | 10-Q | |||
6/30/18 | 10-Q | |||
3/31/18 | 10-Q | |||
12/31/17 | 10-K, 10-K/A | |||
12/19/17 | 3, 4, 8-K, 8-K/A | |||
List all Filings |